АНТИБИОТИК-АССОЦИИРОВАННАЯ ДИАРЕЯ: АКТУАЛЬНОСТЬ ПРОБЛЕМЫ, ПРОФИЛАКТИКА И ТЕРАПИЯ

антибактериальная терапия, побочные эффекты, антибиотик-ассоциированная диарея, профилактика, лечение, мультивидовые пробиотики, РиоФлора Баланс Нео

1. Вялов С.С., Бакулин И.Г., Хурасева А.Б., Яковлев А.А. Эффективность комплексных пробиотиков при запорах у беременных женщин // «Архивъ внутренней медицины». 2013; 1(9): С. 14–18.

2. Самсонов А.А., Плотникова Е.Ю. Антибиотики: друзья или враги, как найти консенсус? Взгляд гастроэнтеролога на антибиотик-ассоциированную диарею // Трудный пациент 2012. No6.С.16-24.

3. Шевяков М.А. Антибиотик-ассоциированная диарея и кандидоз кишечника: возможности лечения и профилактики // Антибиотики и химиотерапия. 2004. Т. 49. No 1(9). С. 26–29.

4. Шендеров Б.А. Медицинская микробная экология и функциональное питание. Т.3. Пробиотики и функциональное питание. М.: Изд-во Грантъ. 2001. 287 с.

5. Avesani V., Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection // Infect Immunol 1994; 62: 384–389.

6. Bartlett J.G. Antibiotic-associated diarrhea // Clin Infect Dis 1992. Vol. 15: 573–81.

7. Bulusu M., Narayan S., Shetler K., Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea // Am J Gastroenterol 2000; 95: 3137–3141.

8. Cremonini F. et al. Meta–analysis: the effect of probiotic administration on antibiotic–associated diarrhoea // Aliment Pharmacol Ther. 2002. Vol. 16 (8). Р. 1461–1467.

9. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile–associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee // Am J Gastroenterol 1997. Vol. 92. Р. 739–750.

10. Fekety R., Silva J., Kauffman C. et al: Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: Comparison of two dosage regimens // Am. J. Med. 1989. Vol. 86. Р. 15–19.

11. Fredenucci I., Chomarat M., Boucaud C., Flandrois J.P. Saccharomyces boulardii fungemia in a patient receiving ultra-levered therapy // Clin Infect Dis 1998. Vol. 27 (1). Р. 222–223.

12. Gilbert D.N. Aspects of the safety profile of oral antimicrobial agents // Infect Dis Clin Pract 1995. Vol. 4(2). Р. 103–112.

13. Guzman R., Kirkpatrick J., Forward K., Lim F. Failure of parenteral metronidazole in the treatment of pseudomembranous colitis // J Infect Dis 1989. Vol. 159. Р. 1154–1155.

14. Hempel S., Newberry S.J., Maher A.R. et al. Probiotics for the Prevention and Treatment of Antibiotic-Associated Diarrhea. A Systematic Review and Meta-analysis // JAMA 2012. Vol. 307 (18). Р. 1959–1969.

15. Hogenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea // Clinical Infec- tious Diseases 1998. Vol. 27 (4). Р. 702–710.

16. Hogenauer C., Langner C., Krause R. et al. Antibiotic-associated segmental hemorrhagic colitis: clinical features, and influence of Klebsiella oxytoca in its pathogenesis // Abstracts of 12 UEGW, Gut 2004. Vol. 53 (VI). Р. A135.

17. Idem А. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea // Lancet 2001. Vol. 357. Р. 189–93.

18. Koning C.J., Jonkers D.M., Stobberingh E.E., Mulder L., Rombouts F.M., Stockbrugger R.W. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxicillin // The Am J Gastroenterol. 2008. . Vol. 103. Р. 178–189.

19. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A // N Engl J Med 2000; 342. Р. 390–7.

20. Land M.H., Rouster-Stevens K., Woods C.R. et al. Lactobacillus sepsis associated with probiotic therapy // Pediatrics 2005; 115 (1). Р. 178–181.

21. Lestin F., Pertschy A., Rimek D. Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities // Dtsch MedWochenschr 2003; 128 (48). Р. 2531–2533.

22. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea // Dig Dis 1998; 16: 292–307.

23. McFarland L.V. Meta-analysis of probiotics for the prevention of an- tibiotic associated diarrhea and the treatment of Clostridium difficile disease // Am J Gastroenterol 2006. Vol. 101 (4). Р. 812–822.

24. McFarland L.V., Mulligan M.E., Kwok R.Y.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile infection // N Engl J Med 1989. Vol. 320: 204–210.

25. Piechno S., Seguin P., Gangneux J.P. Saccharomyces boulardii fungal sepsis: beware of the yeast // Can J Anaesth 2007; 54 (3). Р. 245–246.

26. Riggs M.M., Sethi A.K., Zabarsky T.F. et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents // Clin Infect Dis 2007. Vol. 45. Р. 992.

27. Riquelme A.J., Calvo M.A., Guzma ́n A.M. et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients // J Clin Gastroenterol 2003. Vol. 36 (1). Р. 41–43.

28. Sazawal S., Hiremath G., Dhingra U., Malik P., Deb S., Black R.E. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomized, placebo-controlled trials // Lancet Infect. Dis. Vol. 6. P. 374-382.

29. Starr J. Clostridium difficile-associated diarrhoea: diagnosis and treatment // BMJ 2005. Vol. 331: 498–501.

30. Trautmann M., Synowzik I., Nadji-Ohl M. et al. Fungemia due to Saccharomyces cerevisiae var boulardii. // Chemotherapie Journal 2008. Vol. 17 (2). Р. 57–61.

31. Wistrom J., Norrby S.R., Myhre E.B. et al. Frequency of antibiotic- associated diarrhea in 2462 antibiotic-treated hospitalized patients: a prospective study // Journal of Antimicrobial Chemotherapy 2001. Vol. 47. Р. 43–50.

32. Zunic P., Lacotte J., Pegoix M. et al. Saccharomyces boulardii funge- mia // Therapie 1991. Vol. 46 (6). Р. 498–499.